Scotiabank Begins Coverage on Danaher (NYSE:DHR)

Research analysts at Scotiabank started coverage on shares of Danaher (NYSE:DHR) in a report issued on Monday, Marketbeat.com reports. The firm set a “sector perform” rating and a $265.00 price target on the conglomerate’s stock. Scotiabank’s price target suggests a potential upside of 14.84% from the company’s current price.

DHR has been the subject of several other reports. Royal Bank of Canada reduced their price objective on Danaher from $333.00 to $311.00 and set an “outperform” rating for the company in a research report on Wednesday, October 23rd. Stephens restated an “overweight” rating and issued a $315.00 price target on shares of Danaher in a research report on Wednesday, October 23rd. Bank of America raised shares of Danaher from a “neutral” rating to a “buy” rating and set a $290.00 price objective for the company in a research report on Friday, December 13th. Robert W. Baird decreased their target price on Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a research report on Wednesday, October 23rd. Finally, Wolfe Research raised Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price target for the company in a report on Thursday, October 31st. Six equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $287.05.

Danaher Price Performance

NYSE DHR opened at $230.75 on Monday. The company has a market cap of $166.66 billion, a P/E ratio of 44.04, a P/E/G ratio of 4.33 and a beta of 0.83. Danaher has a 1 year low of $222.53 and a 1 year high of $281.70. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. The company has a fifty day simple moving average of $242.22 and a 200 day simple moving average of $256.09.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.57 by $0.14. Danaher had a return on equity of 10.62% and a net margin of 16.39%. The company had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same period last year, the business posted $2.02 earnings per share. The firm’s revenue was up 3.1% compared to the same quarter last year. On average, sell-side analysts predict that Danaher will post 7.5 EPS for the current year.

Hedge Funds Weigh In On Danaher

Several institutional investors have recently bought and sold shares of DHR. nVerses Capital LLC bought a new stake in shares of Danaher during the second quarter valued at approximately $25,000. Teachers Insurance & Annuity Association of America acquired a new position in Danaher during the 3rd quarter worth $39,000. MidAtlantic Capital Management Inc. bought a new position in Danaher in the 3rd quarter valued at $40,000. FSA Wealth Management LLC acquired a new stake in shares of Danaher in the 3rd quarter valued at $50,000. Finally, Darwin Wealth Management LLC bought a new stake in shares of Danaher during the third quarter worth $55,000. Institutional investors own 79.05% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.